Landos Biopharma Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2023	2022	2021
Market Capitalization	70	11	20	193
Market Cap Growth	-	-43.34%	-89.58%	-
Enterprise Value	33	-26	-24	102
PE Ratio	-0.52	-0.52	-0.51	-5.03
PB Ratio	2.21	0.36	0.51	2.53
P/FCF Ratio	-0.56	-0.56	-0.44	-7.02
P/OCF Ratio	-0.56	-0.56	-0.44	-7.14
EV/EBITDA Ratio	1.19	1.19	0.63	-2.67
EV/EBIT Ratio	1.19	1.19	0.62	-2.66
EV/FCF Ratio	1.28	1.28	0.53	-3.72
Quick Ratio	6.01	6.01	7.25	5.47
Current Ratio	6.09	6.09	7.39	5.55
Return on Equity (ROE)	-54.90%	-54.90%	-79.80%	-40.80%
Return on Assets (ROA)	-49.10%	-49.10%	-68.20%	-36.00%
Return on Capital (ROIC)	-71.49%	-71.49%	-103.65%	-74.50%
Earnings Yield	-31.28%	-192.29%	-195.10%	-19.89%
FCF Yield	-29.20%	-179.51%	-226.22%	-14.24%
Buyback Yield / Dilution	-55.90%	-55.90%	-7.18%	-207.16%
Total Shareholder Return	-55.90%	-55.90%	-7.18%	-207.16%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).